HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

504.495

+4.5040.90%

Number of Gainers:16

Number of Losers:14

Number of Flat:4

PE:- -

High:505.313

Open:500.023

Low:490.944

Close:499.991

Loading ...

Brii Biosciences Ltd. Conducted Annual General Meeting

JW Cayman Therapeutics Co. Ltd. Held Extraordinary General Meeting

Akeso Hits Snag with Less Favorable Clinical Trial Data for Lung Cancer Treatment; Shares Rise 7%

MT Newswires Live

BUZZ-Alphamab Oncology drops most in three weeks as majority shareholder cuts stake

Alphamab Oncology Announces Promising Research Updates on JSKN003 at 2025 ASCO Annual Meeting

Alphamab Oncology Announces Placing of Existing Shares by Controlling Shareholder Rubymab Ltd. Through Morgan Stanley & Co. International plc

Alphamab Oncology - Rubymab Ltd. to Place 14.6 Mln Shares at HK$8.05 Each

THOMSON REUTERS

BRIEF-Zai Lab Presents Positive Phase 1 Data For Zl-1310, A Dll3-Targeted Adc

MicroPort CardioFlow Medtech Unit to Acquire Balance Stake in Medical Device Firm

MT Newswires Live

Zylox-Tonbridge Announces Share Repurchase of 80,000 Shares for HKD 1,492,250 in HKEX Disclosure Filing

Zai Lab Ltd. Announces New Clinical Trial Plans for ZL-1310 in Extensive-Stage Small Cell Lung Cancer Following Promising Phase 1 Results

Zai Lab Presents Positive Phase 1 Data for Zl-1310, a Dll3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients With Extensive-Stage Small Cell Lung Cancer at 2025 Asco Annual Meeting

THOMSON REUTERS

Immunotech Biopharm CEO/CTO Resigns

MT Newswires Live

CARsgen Therapeutics Receives Breakthrough Therapy Designation and Priority Review for Satri-cel in Advanced Gastric Cancer Treatment

Zai Lab and Novocure Announce Results From the Phase 3 Panova-3 Trial of Tumor Treating Fields (Ttfields) Therapy for Pancreatic Cancer to Be Presented at 2025 Asco Annual Meeting

THOMSON REUTERS

MicroPort CardioFlow Announces Acquisition of Remaining 49% Stake in MP CardioAdvent

Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs

Microport Cardioflow Medtech - Total Consideration of Acquisition Is RMB170.9 Mln

THOMSON REUTERS

Microport Cardioflow Medtech - Upon Completion, MP Cardioadvent Will Become a Wholly-Owned Subsidiary of Co

THOMSON REUTERS

Microport Cardioflow Medtech - Microport Sinica and Shanghai Zuoqing Conditionally Agreed to Sell 35.27% and 13.73% Stake in MP Cardioadvent

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1574/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":504.49472,"timestamp":1749197315343,"preClose":499.99072,"halted":0,"volume":133942207,"delay":0,"changeRate":0.009008,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":4.503998,"latestTime":"06-06 16:00:00","open":500.0226,"high":505.3134,"low":490.94357,"amount":2424247939,"amplitude":0.02874,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749432600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":4.144536,"peRate":-25.524806,"turnoverRate":0.005008,"increases":16,"decrements":13,"flats":4,"marketCap":294601588992,"floatMarketCap":270286158640},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":505.3134,"amplitude":0.02874,"preClose":499.99072,"low":490.94357,"pbRate":"4.144536","latestPrice":504.49472,"volume":133942207,"delay":0,"open":500.0226,"prevYearClose":331.1933,"prevWeekClose":491.683,"prevMonthClose":491.683,"prevQuarterClose":455.082,"fiveDayClose":491.683,"twentyDayClose":458.671,"sixtyDayClose":437.197,"secType":"PLATE","market":"HK","turnoverRate":0.005008,"peRate":-25.524806,"marketCap":294601588992,"floatMarketCap":270286158640,"timestamp":1749197315343,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":16,"down":14,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540969779","title":"Brii Biosciences Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540969779","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540969779?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:00","pubTimestamp":1748952047,"startTime":"0","endTime":"0","summary":"Brii Biosciences Ltd. held its annual general meeting on June 3, 2025. During the meeting, several proposals were voted on. The proposal to adopt the audited consolidated financial statements for the year ended December 31, 2024, was approved. The re-election of Dr. Ankang Li as an executive Director was also approved. Additionally, Mr. Gregg Huber Alton and Mr. Yiu Wa Alec Tsui were re-elected as independent non-executive Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL5qVDBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1587","02137"],"gpt_icon":0},{"id":"2540779388","title":"JW Cayman Therapeutics Co. Ltd. Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540779388","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540779388?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:50","pubTimestamp":1748951410,"startTime":"0","endTime":"0","summary":"JW Cayman Therapeutics Co. Ltd. held an extraordinary general meeting on June 3, 2025. During the meeting, a proposal to approve, ratify, and confirm the License Agreement and its execution, along with the implementation of the transactions contemplated under the agreement, was put forward. This proposal was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL7Wd6pM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02126","BK1161","BK1583"],"gpt_icon":0},{"id":"2540478427","title":"Akeso Hits Snag with Less Favorable Clinical Trial Data for Lung Cancer Treatment; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540478427","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540478427?lang=en_us&edition=fundamental","pubTime":"2025-06-03 14:41","pubTimestamp":1748932906,"startTime":"0","endTime":"0","summary":"Akeso  and Summit Therapeutics suffered a setback after less favorable clinical data for its ivonescimab lung cancer drug diminished hopes for approval, the South China Morning Post reported Monday.The US Food and Drug Administration indicated a \"statistically significant\" overall survival benefit, from start of treatment to death, not just delayed tumor progression, is needed for US approval, the report said, citing Summit.The drug showed progression-free survival but had not yet shown a good enough survival benefit for patients in its study for US approval, the report said.Shares in Akeso jumped 7% during afternoon trading on Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09926","BK1161","LU2488822045.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU0348784397.USD","IE00B5MMRT66.SGD","LU1720050803.USD","LU0348783233.USD","IE00B543WZ88.USD","BK1574","LU0417516571.SGD"],"gpt_icon":1},{"id":"2540710242","title":"BUZZ-Alphamab Oncology drops most in three weeks as majority shareholder cuts stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2540710242","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540710242?lang=en_us&edition=fundamental","pubTime":"2025-06-03 10:06","pubTimestamp":1748916384,"startTime":"0","endTime":"0","summary":"BUZZ-Alphamab Oncology drops most in three weeks as majority shareholder cuts stake ** Shares of Alphamab Oncology 9966.HK drop 11.8% to HK$8.07, their biggest intraday pct decline since May 12** Stock hits the lowest since May 21, and on course to snap three straight sessions of gains, if current trend holds ** Alphamab Oncology says controlling shareholder plans to sell 14.6 mln existing shares at HK$8.05 each in share placement, reducing its stake to 31% from 32.5%** Co says the controlling shareholder will use the proceeds to repay existing personal liabilities and debts, and the placement is not expected to have any impact on its business or operations** The Hang Seng Biotech Index .HSHKBIO gains 1.3% and the Hang Seng Index .HSI climbs 1.2%** Alphamab stock up 133.7%, YTD    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nL2N3S601J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2540005719","title":"Alphamab Oncology Announces Promising Research Updates on JSKN003 at 2025 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540005719","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540005719?lang=en_us&edition=fundamental","pubTime":"2025-06-03 07:43","pubTimestamp":1748907787,"startTime":"0","endTime":"0","summary":"Alphamab Oncology has announced research updates for their drug JSKN003, which were presented at the 2025 ASCO Annual Meeting held from May 30 to June 3. The updates are based on findings from two clinical studies, JSKN003-101 and JSKN003-102. JSKN003-101 is a first-in-human, open-label, multi-center phase I clinical study conducted in Australia, focusing on patients with advanced or metastatic solid tumors. Meanwhile, JSKN003-102 is a phase I/II clinical study carried out in China, targeting patients with advanced solid tumors. These studies evaluate the efficacy and safety of JSKN003 for various indications. Alphamab Oncology emphasizes its proprietary protein engineering platforms and aims to develop multifunctional biological drug candidates to benefit patients globally. However, the company advises cautious handling of its shares, as successful development and marketing of JSKN003 are not guaranteed.Disclaimer: This news brief was created by Public Technologies  using generative a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL83bGgr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2540071979","title":"Alphamab Oncology Announces Placing of Existing Shares by Controlling Shareholder Rubymab Ltd. Through Morgan Stanley & Co. International plc","url":"https://stock-news.laohu8.com/highlight/detail?id=2540071979","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540071979?lang=en_us&edition=fundamental","pubTime":"2025-06-03 07:34","pubTimestamp":1748907250,"startTime":"0","endTime":"0","summary":"Alphamab Oncology Announces Placing of Existing Shares by Controlling Shareholder Rubymab Ltd. Through Morgan Stanley & Co. International plc. On June 2, 2025, Alphamab Oncology announced that its controlling shareholder, Rubymab Ltd., entered into a share placing agreement with Morgan Stanley & Co. International plc as the sole placing agent. The announcement did not specify the total number of shares or the price involved in the transaction. The completion of the placing is subject to certain conditions, and there is no assurance that the transaction will be finalized.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief on June 03, 2025, and is solely respon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLb3h7tB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2133065610.SGD","LU0234570918.USD","LU0314104364.USD","LU0158827948.USD","LU2023251221.USD","LU2089284900.SGD","LU1720051108.HKD","BK4127","LU0320765646.SGD","LU0795875086.SGD","LU2028103732.USD","BK1161","LU1074936037.SGD","BK4516","LU2089283258.USD","LU1363072403.SGD","BK1574","LU1989772923.USD","LU0912757837.SGD","LU1162221912.USD","LU0106831901.USD","IE00BZ1G4Q59.USD","09966","LU0098860793.USD","LU0158827781.USD","LU1732800096.USD","LU0106261372.USD","LU2111349929.HKD","LU1989772840.SGD","LU0225283273.USD","LU1668664300.SGD","LU2357305700.SGD","BK4588","LU1720051017.SGD","LU2347655156.SGD","LU0267386448.USD","BK4534","BK4585","LU1732799900.SGD","LU0971096721.USD","BK4504","LU0006306889.USD","LU0795875169.SGD","LU2271345857.HKD","BK4581","LU1548497426.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2540719277","title":"Alphamab Oncology - Rubymab Ltd. to Place 14.6 Mln Shares at HK$8.05 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2540719277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540719277?lang=en_us&edition=fundamental","pubTime":"2025-06-03 07:31","pubTimestamp":1748907066,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nFWN3S50T5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2540798254","title":"BRIEF-Zai Lab Presents Positive Phase 1 Data For Zl-1310, A Dll3-Targeted Adc","url":"https://stock-news.laohu8.com/highlight/detail?id=2540798254","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540798254?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:32","pubTimestamp":1748867555,"startTime":"0","endTime":"0","summary":"BRIEF-Zai Lab Presents Positive Phase 1 Data For Zl-1310, A Dll3-Targeted AdcJune 2 (Reuters) - Zai Lab Ltd 9688.HK:ZAI LAB PRESENTS POSITIVE PHASE 1 DATA FOR ZL-1310, A DLL3-TARGETED ADC, DEMONSTRATI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA7PNBG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK1161","LU2488822045.USD","BK1574","BK1588"],"gpt_icon":0},{"id":"2540798981","title":"MicroPort CardioFlow Medtech Unit to Acquire Balance Stake in Medical Device Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2540798981","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540798981?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:24","pubTimestamp":1748867084,"startTime":"0","endTime":"0","summary":"A unit of MicroPort CardioFlow Medtech  agreed to purchase the remaining 49% equity stake it does not already own in Shanghai MicroPort CardioAdvent for 170.9 million yuan, a Friday Hong Kong bourse filing said.Shanghai MicroPort CardioFlow Medtech will buy a 35.27% stake from MicroPort Sinica and 13.73% from Shanghai Zuoqing Enterprise Management Consulting Service Centre.Upon completion, it will own 100% of the target company, the filing said.Shanghai MicroPort CardioAdvent is a high-tech medical device firm specializing in left atrial appendage devices.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1100","02160","BK1574"],"gpt_icon":0},{"id":"2540807760","title":"Zylox-Tonbridge Announces Share Repurchase of 80,000 Shares for HKD 1,492,250 in HKEX Disclosure Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2540807760","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540807760?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:37","pubTimestamp":1748864269,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge Medical Technology Co., Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 160,000 shares. The total aggregate price paid for the repurchase was HKD 1,492,250. The repurchased shares are being held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL7HnTtV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1100","02190","BK1574","BK1587"],"gpt_icon":0},{"id":"2540762059","title":"Zai Lab Ltd. Announces New Clinical Trial Plans for ZL-1310 in Extensive-Stage Small Cell Lung Cancer Following Promising Phase 1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2540762059","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540762059?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:01","pubTimestamp":1748862060,"startTime":"0","endTime":"0","summary":"Zai Lab Ltd. Announces New Clinical Trial Plans for ZL-1310 in Extensive-Stage Small Cell Lung Cancer Following Promising Phase 1 Results. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire  on June 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL3TD43T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1588","09688","LU2488822045.USD"],"gpt_icon":0},{"id":"2540200762","title":"Zai Lab Presents Positive Phase 1 Data for Zl-1310, a Dll3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients With Extensive-Stage Small Cell Lung Cancer at 2025 Asco Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540200762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540200762?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:00","pubTimestamp":1748862001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA7PNBG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","09688","BK1588","BK1161","BK1574"],"gpt_icon":0},{"id":"2540454764","title":"Immunotech Biopharm CEO/CTO Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2540454764","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540454764?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:19","pubTimestamp":1748859580,"startTime":"0","endTime":"0","summary":"Immunotech Biopharm  Chief Executive Officer and Chief Technology Officer Wang Yu will step down, effective June 25, according to a Friday filing with the Hong Kong bourse.Senior Vice President Zhang Jian will become acting CEO, the filing said.The drug company will seek candidates for the CEO and CTO posts, it said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06978","BK4160","CTO","BK1574"],"gpt_icon":0},{"id":"2540537557","title":"CARsgen Therapeutics Receives Breakthrough Therapy Designation and Priority Review for Satri-cel in Advanced Gastric Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540537557","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540537557?lang=en_us&edition=fundamental","pubTime":"2025-06-02 08:15","pubTimestamp":1748823320,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Receives Breakthrough Therapy Designation and Priority Review for Satri-cel in Advanced Gastric Cancer Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via PR Newswire  on June 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLbJRgJf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1587","02171","BK1161","BK1585"],"gpt_icon":0},{"id":"2540784206","title":"Zai Lab and Novocure Announce Results From the Phase 3 Panova-3 Trial of Tumor Treating Fields (Ttfields) Therapy for Pancreatic Cancer to Be Presented at 2025 Asco Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540784206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540784206?lang=en_us&edition=fundamental","pubTime":"2025-06-01 03:09","pubTimestamp":1748718542,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nTUA5RVPXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU2488822045.USD","BK1588","BK1574","09688"],"gpt_icon":0},{"id":"2539275550","title":"MicroPort CardioFlow Announces Acquisition of Remaining 49% Stake in MP CardioAdvent","url":"https://stock-news.laohu8.com/highlight/detail?id=2539275550","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539275550?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:45","pubTimestamp":1748616322,"startTime":"0","endTime":"0","summary":"MicroPort CardioFlow Medtech Corporation announced a discloseable and connected transaction to acquire the remaining 49% equity interest in MP CardioAdvent. This acquisition, detailed in an agreement dated May 30, 2025, involves purchasing approximately 35.27% from MicroPort Sinica and 13.73% from Shanghai Zuoqing. Upon completion, MP CardioFlow will fully own MP CardioAdvent, enhancing its focus on innovative solutions for structural heart diseases. The transaction, subject to regulatory approvals, is significant under the listing rules due to its size.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Cardioflow Medtech Corporation published the original content used to generate this news brief on May 30, 2025, and is solely r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL7J0n5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","00853","BK1585","BK1100","BK1574","BK1589","02160"],"gpt_icon":0},{"id":"2539275394","title":"Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2539275394","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539275394?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:43","pubTimestamp":1748616210,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has been involved in legal proceedings with Viking Therapeutics, Inc. over the importation of its drug candidates, ASC41 and ASC43F. In October 2024, the United States International Trade Commission issued an initial determination finding a violation of Section 337, recommending a seven-year exclusion order for these drugs. ASC41 is developed for treating non-alcoholic steatohepatitis  and targets thyroid hormone receptor beta , while ASC43F is a fixed-dose combination targeting both THRβ and farnesoid X receptor  for NASH treatment. Despite the ruling, Ascletis believes the outcome will not have a material adverse effect on its business and is seeking legal advice for an appeal. The company is committed to protecting its trade secrets and will provide updates on any significant developments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL48bdv9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1574","BK4139","BK4588","BK1161","VKTX","BK1515","BK4599","BK4585"],"gpt_icon":0},{"id":"2539427302","title":"Microport Cardioflow Medtech - Total Consideration of Acquisition Is RMB170.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2539427302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539427302?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:36","pubTimestamp":1748615784,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S230K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","02160","BK1100","BK1574"],"gpt_icon":0},{"id":"2539273022","title":"Microport Cardioflow Medtech - Upon Completion, MP Cardioadvent Will Become a Wholly-Owned Subsidiary of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2539273022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539273022?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:36","pubTimestamp":1748615784,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S230K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1100","BK1583","02160"],"gpt_icon":0},{"id":"2539021273","title":"Microport Cardioflow Medtech - Microport Sinica and Shanghai Zuoqing Conditionally Agreed to Sell 35.27% and 13.73% Stake in MP Cardioadvent","url":"https://stock-news.laohu8.com/highlight/detail?id=2539021273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539021273?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:36","pubTimestamp":1748615784,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S230K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1100","02160","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":74,"code":"91000000","status":"200"}]}}